EP1670901A2 - Method of in vitro differentiation of neural stem cells, motor neurons and dopamine neurons from primate embryonic stem cells - Google Patents
Method of in vitro differentiation of neural stem cells, motor neurons and dopamine neurons from primate embryonic stem cellsInfo
- Publication number
- EP1670901A2 EP1670901A2 EP04782339A EP04782339A EP1670901A2 EP 1670901 A2 EP1670901 A2 EP 1670901A2 EP 04782339 A EP04782339 A EP 04782339A EP 04782339 A EP04782339 A EP 04782339A EP 1670901 A2 EP1670901 A2 EP 1670901A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- cells
- neurons
- population
- neural
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 76
- 210000001671 embryonic stem cell Anatomy 0.000 title claims abstract description 15
- 210000002569 neuron Anatomy 0.000 title claims description 173
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 title claims description 132
- 229960003638 dopamine Drugs 0.000 title claims description 66
- 210000002161 motor neuron Anatomy 0.000 title claims description 65
- 210000001178 neural stem cell Anatomy 0.000 title claims description 10
- 230000004069 differentiation Effects 0.000 title description 74
- 238000000338 in vitro Methods 0.000 title description 21
- 241000288906 Primates Species 0.000 title description 5
- 210000004027 cell Anatomy 0.000 claims abstract description 527
- 230000001537 neural effect Effects 0.000 claims abstract description 123
- 101100310657 Mus musculus Sox1 gene Proteins 0.000 claims abstract description 66
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims abstract description 60
- 102100035290 Fibroblast growth factor 13 Human genes 0.000 claims abstract description 59
- 102000007354 PAX6 Transcription Factor Human genes 0.000 claims abstract description 49
- 101150081664 PAX6 gene Proteins 0.000 claims abstract description 48
- 238000012258 culturing Methods 0.000 claims abstract description 10
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 claims abstract description 8
- 101001060274 Homo sapiens Fibroblast growth factor 4 Proteins 0.000 claims abstract description 8
- 102100037665 Fibroblast growth factor 9 Human genes 0.000 claims abstract description 6
- 101001027380 Homo sapiens Fibroblast growth factor 9 Proteins 0.000 claims abstract description 6
- 102100037680 Fibroblast growth factor 8 Human genes 0.000 claims abstract 6
- 101001027382 Homo sapiens Fibroblast growth factor 8 Proteins 0.000 claims abstract 6
- 210000001259 mesencephalon Anatomy 0.000 claims description 62
- 210000002242 embryoid body Anatomy 0.000 claims description 31
- 238000011161 development Methods 0.000 claims description 30
- 230000018109 developmental process Effects 0.000 claims description 30
- 210000004129 prosencephalon Anatomy 0.000 claims description 29
- 101000576323 Homo sapiens Motor neuron and pancreas homeobox protein 1 Proteins 0.000 claims description 21
- 238000012360 testing method Methods 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 11
- 239000003102 growth factor Substances 0.000 claims description 9
- 210000003061 neural cell Anatomy 0.000 claims description 9
- 230000001360 synchronised effect Effects 0.000 claims description 9
- 108091006774 SLC18A3 Proteins 0.000 claims description 6
- 102100039452 Vesicular acetylcholine transporter Human genes 0.000 claims description 6
- 101100451924 Mus musculus Hoxb6 gene Proteins 0.000 claims description 5
- 101100071843 Mus musculus Hoxb1 gene Proteins 0.000 claims description 4
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 claims description 4
- 229960004373 acetylcholine Drugs 0.000 claims description 4
- 230000001902 propagating effect Effects 0.000 claims description 4
- 230000011712 cell development Effects 0.000 claims 3
- 102100038238 Aromatic-L-amino-acid decarboxylase Human genes 0.000 claims 2
- 101710151768 Aromatic-L-amino-acid decarboxylase Proteins 0.000 claims 2
- 101001123678 Homo sapiens Phenylethanolamine N-methyltransferase Proteins 0.000 claims 2
- 102100024611 Phosphatidylethanolamine N-methyltransferase Human genes 0.000 claims 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 72
- 239000002243 precursor Substances 0.000 description 56
- 102000003693 Hedgehog Proteins Human genes 0.000 description 45
- 108090000031 Hedgehog Proteins Proteins 0.000 description 45
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 45
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 45
- 239000002609 medium Substances 0.000 description 42
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 40
- 229930002330 retinoic acid Natural products 0.000 description 40
- 229960001727 tretinoin Drugs 0.000 description 40
- 102000003956 Fibroblast growth factor 8 Human genes 0.000 description 34
- 108090000368 Fibroblast growth factor 8 Proteins 0.000 description 34
- 241000699666 Mus <mouse, genus> Species 0.000 description 33
- 238000011282 treatment Methods 0.000 description 33
- 230000015572 biosynthetic process Effects 0.000 description 32
- 230000014509 gene expression Effects 0.000 description 26
- 238000005755 formation reaction Methods 0.000 description 25
- 210000004556 brain Anatomy 0.000 description 23
- 102100025170 Motor neuron and pancreas homeobox protein 1 Human genes 0.000 description 20
- 230000036982 action potential Effects 0.000 description 19
- 101100285407 Mus musculus En1 gene Proteins 0.000 description 18
- 210000002777 columnar cell Anatomy 0.000 description 18
- 210000000276 neural tube Anatomy 0.000 description 18
- 210000000461 neuroepithelial cell Anatomy 0.000 description 18
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 17
- 230000008569 process Effects 0.000 description 17
- 102100023460 Choline O-acetyltransferase Human genes 0.000 description 16
- 108010058699 Choline O-acetyltransferase Proteins 0.000 description 16
- 102000008730 Nestin Human genes 0.000 description 15
- 108010088225 Nestin Proteins 0.000 description 15
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 15
- 238000012744 immunostaining Methods 0.000 description 15
- 210000005055 nestin Anatomy 0.000 description 15
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 14
- 102000040945 Transcription factor Human genes 0.000 description 14
- 108091023040 Transcription factor Proteins 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 14
- 108010007093 dispase Proteins 0.000 description 14
- 230000002269 spontaneous effect Effects 0.000 description 14
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 230000006698 induction Effects 0.000 description 12
- 239000003550 marker Substances 0.000 description 12
- 210000000278 spinal cord Anatomy 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 11
- 101150092239 OTX2 gene Proteins 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 239000010410 layer Substances 0.000 description 10
- 210000004940 nucleus Anatomy 0.000 description 10
- 230000000946 synaptic effect Effects 0.000 description 10
- 238000002054 transplantation Methods 0.000 description 10
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 9
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 9
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 9
- 210000003050 axon Anatomy 0.000 description 9
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 9
- 210000001176 projection neuron Anatomy 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- BAQMYDQNMFBZNA-UHFFFAOYSA-N N-biotinyl-L-lysine Natural products N1C(=O)NC2C(CCCCC(=O)NCCCCC(N)C(O)=O)SCC21 BAQMYDQNMFBZNA-UHFFFAOYSA-N 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- BAQMYDQNMFBZNA-MNXVOIDGSA-N biocytin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCC[C@H](N)C(O)=O)SC[C@@H]21 BAQMYDQNMFBZNA-MNXVOIDGSA-N 0.000 description 8
- 238000010348 incorporation Methods 0.000 description 8
- QMGVPVSNSZLJIA-FVWCLLPLSA-N strychnine Chemical compound O([C@H]1CC(N([C@H]2[C@H]1[C@H]1C3)C=4C5=CC=CC=4)=O)CC=C1CN1[C@@H]3[C@]25CC1 QMGVPVSNSZLJIA-FVWCLLPLSA-N 0.000 description 8
- 101150004541 HOXC8 gene Proteins 0.000 description 7
- 239000012981 Hank's balanced salt solution Substances 0.000 description 7
- 102100024392 Insulin gene enhancer protein ISL-1 Human genes 0.000 description 7
- 102000008763 Neurofilament Proteins Human genes 0.000 description 7
- 108010088373 Neurofilament Proteins Proteins 0.000 description 7
- 230000001464 adherent effect Effects 0.000 description 7
- 229960005070 ascorbic acid Drugs 0.000 description 7
- 235000010323 ascorbic acid Nutrition 0.000 description 7
- 239000011668 ascorbic acid Substances 0.000 description 7
- 102000014823 calbindin Human genes 0.000 description 7
- 108060001061 calbindin Proteins 0.000 description 7
- 210000003169 central nervous system Anatomy 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000002955 isolation Methods 0.000 description 7
- 230000003988 neural development Effects 0.000 description 7
- 210000005044 neurofilament Anatomy 0.000 description 7
- 230000004031 neuronal differentiation Effects 0.000 description 7
- 210000004248 oligodendroglia Anatomy 0.000 description 7
- 238000007747 plating Methods 0.000 description 7
- 238000003757 reverse transcription PCR Methods 0.000 description 7
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 6
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 6
- 101001053263 Homo sapiens Insulin gene enhancer protein ISL-1 Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 210000005056 cell body Anatomy 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 239000000306 component Substances 0.000 description 6
- 230000002999 depolarising effect Effects 0.000 description 6
- 230000002255 enzymatic effect Effects 0.000 description 6
- 230000002964 excitative effect Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 210000001161 mammalian embryo Anatomy 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 5
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 5
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 5
- 108010002822 Phenylethanolamine N-Methyltransferase Proteins 0.000 description 5
- 102100028917 Phenylethanolamine N-methyltransferase Human genes 0.000 description 5
- 102100034026 RNA-binding protein Musashi homolog 1 Human genes 0.000 description 5
- 101710129077 RNA-binding protein Musashi homolog 1 Proteins 0.000 description 5
- 210000001130 astrocyte Anatomy 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 210000004748 cultured cell Anatomy 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 229940050410 gluconate Drugs 0.000 description 5
- 229960002897 heparin Drugs 0.000 description 5
- 229920000669 heparin Polymers 0.000 description 5
- 210000001020 neural plate Anatomy 0.000 description 5
- 230000000644 propagated effect Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 210000000130 stem cell Anatomy 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 5
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 4
- IYGYMKDQCDOMRE-QRWMCTBCSA-N Bicculine Chemical compound O([C@H]1C2C3=CC=4OCOC=4C=C3CCN2C)C(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-QRWMCTBCSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 4
- 101800003838 Epidermal growth factor Proteins 0.000 description 4
- 108700005087 Homeobox Genes Proteins 0.000 description 4
- 108010048671 Homeodomain Proteins Proteins 0.000 description 4
- 102000009331 Homeodomain Proteins Human genes 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 4
- 229930040373 Paraformaldehyde Natural products 0.000 description 4
- 208000018737 Parkinson disease Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 241000283984 Rodentia Species 0.000 description 4
- 108010087230 Sincalide Proteins 0.000 description 4
- 241001279009 Strychnos toxifera Species 0.000 description 4
- 102000001435 Synapsin Human genes 0.000 description 4
- 108050009621 Synapsin Proteins 0.000 description 4
- 238000004115 adherent culture Methods 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- AACMFFIUYXGCOC-UHFFFAOYSA-N bicuculline Natural products CN1CCc2cc3OCOc3cc2C1C4OCc5c6OCOc6ccc45 AACMFFIUYXGCOC-UHFFFAOYSA-N 0.000 description 4
- 210000003855 cell nucleus Anatomy 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- IYGYMKDQCDOMRE-UHFFFAOYSA-N d-Bicucullin Natural products CN1CCC2=CC=3OCOC=3C=C2C1C1OC(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-UHFFFAOYSA-N 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940116977 epidermal growth factor Drugs 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 210000005260 human cell Anatomy 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 210000002241 neurite Anatomy 0.000 description 4
- 210000004498 neuroglial cell Anatomy 0.000 description 4
- 210000000956 olfactory bulb Anatomy 0.000 description 4
- 229920002866 paraformaldehyde Polymers 0.000 description 4
- 108010057417 polysialyl neural cell adhesion molecule Proteins 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 4
- 229960005453 strychnine Drugs 0.000 description 4
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 3
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 3
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 3
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 3
- 108010078791 Carrier Proteins Proteins 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 108700014808 Homeobox Protein Nkx-2.2 Proteins 0.000 description 3
- 102100028098 Homeobox protein Nkx-6.1 Human genes 0.000 description 3
- 101000578254 Homo sapiens Homeobox protein Nkx-6.1 Proteins 0.000 description 3
- 101000979001 Homo sapiens Methionine aminopeptidase 2 Proteins 0.000 description 3
- 101000969087 Homo sapiens Microtubule-associated protein 2 Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102100023174 Methionine aminopeptidase 2 Human genes 0.000 description 3
- 101100232284 Mus musculus Hoxc5 gene Proteins 0.000 description 3
- 101100074807 Mus musculus Lhx3 gene Proteins 0.000 description 3
- 102000019040 Nuclear Antigens Human genes 0.000 description 3
- 108010051791 Nuclear Antigens Proteins 0.000 description 3
- 102000000813 Proto-Oncogene Proteins c-ret Human genes 0.000 description 3
- 108010001648 Proto-Oncogene Proteins c-ret Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 102000004874 Synaptophysin Human genes 0.000 description 3
- 108090001076 Synaptophysin Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 102000004243 Tubulin Human genes 0.000 description 3
- 108090000704 Tubulin Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 210000002459 blastocyst Anatomy 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 229950004398 broxuridine Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 210000005064 dopaminergic neuron Anatomy 0.000 description 3
- 239000003797 essential amino acid Substances 0.000 description 3
- 235000020776 essential amino acid Nutrition 0.000 description 3
- 230000000763 evoking effect Effects 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 210000001320 hippocampus Anatomy 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 210000003016 hypothalamus Anatomy 0.000 description 3
- 210000003078 multipolar neuron Anatomy 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- 230000002474 noradrenergic effect Effects 0.000 description 3
- 229960002748 norepinephrine Drugs 0.000 description 3
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 3
- 108010017843 platelet-derived growth factor A Proteins 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000036390 resting membrane potential Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 210000003523 substantia nigra Anatomy 0.000 description 3
- 210000000225 synapse Anatomy 0.000 description 3
- CFMYXEVWODSLAX-QOZOJKKESA-N tetrodotoxin Chemical compound O([C@@]([C@H]1O)(O)O[C@H]2[C@@]3(O)CO)[C@H]3[C@@H](O)[C@]11[C@H]2[C@@H](O)N=C(N)N1 CFMYXEVWODSLAX-QOZOJKKESA-N 0.000 description 3
- 229950010357 tetrodotoxin Drugs 0.000 description 3
- CFMYXEVWODSLAX-UHFFFAOYSA-N tetrodotoxin Natural products C12C(O)NC(=N)NC2(C2O)C(O)C3C(CO)(O)C1OC2(O)O3 CFMYXEVWODSLAX-UHFFFAOYSA-N 0.000 description 3
- 229950003937 tolonium Drugs 0.000 description 3
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 3
- 230000002110 toxicologic effect Effects 0.000 description 3
- 231100000027 toxicology Toxicity 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 210000004515 ventral tegmental area Anatomy 0.000 description 3
- VOROEQBFPPIACJ-SCSAIBSYSA-N (2r)-2-amino-5-phosphonopentanoic acid Chemical compound OC(=O)[C@H](N)CCCP(O)(O)=O VOROEQBFPPIACJ-SCSAIBSYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- IAWXTSMHXFRLQR-UHFFFAOYSA-N 2,3-bis($l^{1}-oxidanyl)-7-nitroquinoxaline-6-carbonitrile Chemical compound O=C1C(=O)N=C2C=C(C#N)C([N+](=O)[O-])=CC2=N1 IAWXTSMHXFRLQR-UHFFFAOYSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- -1 AADC Proteins 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 241001076388 Fimbria Species 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 238000012897 Levenberg–Marquardt algorithm Methods 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 239000012580 N-2 Supplement Substances 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 206010043276 Teratoma Diseases 0.000 description 2
- 102000000307 Transcription factor SOX-1 Human genes 0.000 description 2
- 108050008750 Transcription factor SOX-1 Proteins 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000000133 brain stem Anatomy 0.000 description 2
- 235000010633 broth Nutrition 0.000 description 2
- 238000004422 calculation algorithm Methods 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000004186 co-expression Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 210000000877 corpus callosum Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 210000001654 germ layer Anatomy 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 210000004884 grey matter Anatomy 0.000 description 2
- 230000000971 hippocampal effect Effects 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 238000002991 immunohistochemical analysis Methods 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000001153 interneuron Anatomy 0.000 description 2
- 238000007914 intraventricular administration Methods 0.000 description 2
- 210000003140 lateral ventricle Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000028161 membrane depolarization Effects 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 208000005264 motor neuron disease Diseases 0.000 description 2
- 210000001577 neostriatum Anatomy 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 230000004766 neurogenesis Effects 0.000 description 2
- 230000014511 neuron projection development Effects 0.000 description 2
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 2
- 230000001242 postsynaptic effect Effects 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000007261 regionalization Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 210000001082 somatic cell Anatomy 0.000 description 2
- 208000020431 spinal cord injury Diseases 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000004114 suspension culture Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000005062 synaptic transmission Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 210000004885 white matter Anatomy 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- RPXVIAFEQBNEAX-UHFFFAOYSA-N 6-Cyano-7-nitroquinoxaline-2,3-dione Chemical compound N1C(=O)C(=O)NC2=C1C=C([N+](=O)[O-])C(C#N)=C2 RPXVIAFEQBNEAX-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108091023043 Alu Element Proteins 0.000 description 1
- 241000269350 Anura Species 0.000 description 1
- FTEDXVNDVHYDQW-UHFFFAOYSA-N BAPTA Chemical compound OC(=O)CN(CC(O)=O)C1=CC=CC=C1OCCOC1=CC=CC=C1N(CC(O)=O)CC(O)=O FTEDXVNDVHYDQW-UHFFFAOYSA-N 0.000 description 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000284156 Clerodendrum quadriloculare Species 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000713575 Homo sapiens Tubulin beta-3 chain Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 108700005092 MHC Class II Genes Proteins 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 101100518992 Mus musculus Pax2 gene Proteins 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 102100021852 Neuronal cell adhesion molecule Human genes 0.000 description 1
- 101710130688 Neuronal cell adhesion molecule Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 108010032788 PAX6 Transcription Factor Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 239000005700 Putrescine Substances 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 101100184491 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) MNR2 gene Proteins 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102100036790 Tubulin beta-3 chain Human genes 0.000 description 1
- 108010020033 Vesicular Monoamine Transport Proteins Proteins 0.000 description 1
- 102000009659 Vesicular Monoamine Transport Proteins Human genes 0.000 description 1
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 description 1
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000002934 adrenergic neuron Anatomy 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 208000036815 beta tubulin Diseases 0.000 description 1
- 229940112869 bone morphogenetic protein Drugs 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 210000004289 cerebral ventricle Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000028436 dopamine uptake Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000000848 glutamatergic effect Effects 0.000 description 1
- 210000000020 growth cone Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 238000013115 immunohistochemical detection Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 108010090448 insulin gene enhancer binding protein Isl-1 Proteins 0.000 description 1
- 210000002660 insulin-secreting cell Anatomy 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 210000002425 internal capsule Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 210000005171 mammalian brain Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012533 medium component Substances 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 238000012895 mono-exponential function Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000006740 morphological transformation Effects 0.000 description 1
- 230000008271 nervous system development Effects 0.000 description 1
- 210000005155 neural progenitor cell Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 101710135378 pH 6 antigen Proteins 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 238000000059 patterning Methods 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000000088 plastic resin Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 150000003385 sodium Chemical class 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 238000009580 stem-cell therapy Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000012762 unpaired Student’s t-test Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0619—Neurons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0623—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
- C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/44—Thiols, e.g. mercaptoethanol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/46—Amines, e.g. putrescine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/119—Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/385—Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/41—Hedgehog proteins; Cyclopamine (inhibitor)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/90—Polysaccharides
- C12N2501/91—Heparin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
Definitions
- Human embryonic stem (ES) cells are pluripotent cells derived from the inner cell mass of pre-implantation embryos (Thomson, J. A., et al., Science 282:1145-1147, 1998). Similar to mouse ES cells, they can be expanded to large numbers while maintaining their potential to differentiate into various somatic cell types of all three germ layers (Thomson, J. A., et al., supra, 1998; Reubinoff, B.E., et al.. Nat. Biotech. 18:399. 2000; Thomson, J.A. and Odorico, J.S.. Trends Biotech 18:53-57, 2000; Amit, M., et al., De ⁇ BjoL 227:271-278, 2000).
- mice ES cells have been found to differentiate in vitro to many clinically relevant cell types, including hematopoietic cells (Wiles, M.V. and Keller, G., Development 111 :259-267. 1991), cardiomyocytes (Klug, M.G., et al.. J. Clin. Invest. 98:216-224. 1996), insulin-secreting cells (Soria, B., et aj., Diabetes 49:157-162. 2000), and neurons and glia (Bain, G.. et al.. Dev. Biol.
- the present invention is a method of creating a population of cells comprising a synchronous population of cells cultured from embryonic stem cells which are characterized by an early rosette morphology and are Sox1 " , Pax6 + .
- the method comprises the steps of: (a) propagating embryonic stem cells into embryoid bodies and (b) propagating embryoid bodies into a synchronous population of neural stem cells in the form of neural tube-like rosettes, wherein this propagation is in the presence of FGF2,
- the total time period between the propagation of embryonic stem cells to development of early rosettes is preferably 8 - 10 days.
- the total population of Pax6 + /Sox1 " cells is at least 70% of the total cell population.
- the present invention is also a population of cells created by this method.
- the invention is a method of creating a population of synchronized neural stem cells wherein the cells are characterized by a neural tube-like rosette morphology and are Pax6 + /Sox1 + , the method comprising the step of culturing cells that are characterized by an early rosette morphology and are Sox1 " , Pax6 + for 4-6 days in the presence of FGF2, FGF4, FGF8, or RA.
- the invention is also a population of cells created by this method.
- the early rosette cells were cultured with FGF8, preferably for 4 - 7 days, and are EN1 + .
- the cells were cultured with FGF2, preferably for 4 - 7 days, and are Bf1 + .
- the cells were cultured with RA, preferably for 4 - 7 days, and are Hox + .
- the invention is a method of isolating a population of midbrain dopamine neurons, comprising the step of culturing the cells described above in the presence of FGF8 with SHH, wherein the resulting cells express TH, AADC, EN-1 , VMAT2 and DAT, but do not express DbH and PNMT.
- the invention is also a population of cells created by this method.
- the invention is a method of isolating a population of spinal motor neurons comprising the step of culturing the cells above described above in the presence of RA with SHH, wherein the resulting cells express HB9, HoxB1 , HoxB6, HoxC5, HoxC ⁇ , ChAT and VAChT.
- the invention is also a population of cells created by this method.
- the present invention is a method of isolating a population of forebrain dopamine neurons comprising the step of culturing the cells described above with SHH.
- the invention is also a population of cells created by this method.
- the present invention is also a method of testing the cell populations described above to screen agents for the ability to affect normal human neural development.
- FIG. 1A-I Differentiation and isolation of neural precursors from ES cells.
- FIG. 1 A An attached EB grown in the presence of FGF2 for five days shows flattened cells at the periphery and small elongated cells congregated in the center.
- Fig. 1 B By seven days, many rosette formations (arrows) appeared in the
- the upper-right inset is the 1- ⁇ m section of the rosette
- rosette center
- Fig. 1C Musashi-1
- Fig. 1 D Musashi-1
- Fig. 1 D Musashi-1
- Fig. 1 E A combined image of Fig. 1C and Fig. 1 D with all cell nuclei labeled with DAPI.
- Fig. 1 F After treatment with dispase for 20 minutes, the rosette formations retracted whereas the surrounding flat cells remained attached.
- Fig. 1G-I Isolated cells are positively stained for nestin in a filamentous pattern (Fig. 1G), Musashi-1 in cytoplasm (Fig. 1 H), and PSA-NCAM
- Fig. 2A-G Characterization of ES cell-derived neural precursors in vitro.
- Fig. 2B Differentiation of a cluster of ES cell-derived neural precursors for three weeks shows neurite bundles with cells migrating along them.
- FIG. 2C Immunostaining after three weeks of differentiation indicates that the majority of cells are ⁇ m-tubulin + neurons (red) and that only a few cells are GFAP + astrocytes (green).
- FIG. 2D After forty-five days of differentiation, many more GFAP + astrocytes (green) appear along with NF200 + neurites (red, yellowish due to overlapping with green GFAP).
- FIG. 3A-K Incorporation and differentiation of ES cell-derived neural precursors in vivo. Grafted cells are detected by in situ hybridization with a probe to the human a/t/-repeat element (Fig. 3A-E, G) or an antibody to a human-specific nuclear antigen (Fig. 3F).
- Fig. 3A Individual donor cells in the host cortex of an eight-week-old recipient (arrows).
- Fig. 3B Extensive incorporation of ES cell- derived neural precursors in the hippocampal formation. Cells hybridized with the human alu probe are labeled with red dots (pseudo-colored).
- FIG. 3C Incorporated human cells in the vicinity of the hippocampal pyramidal layer at P14.
- FIG. 3D ES cell-derived cells in the septum of a four-week-old recipient mouse.
- FIG. 3E High power view of an individual donor cell in the hypothalamus. Note the seamless integration between adjacent unlabeled host cells.
- Fig. 3F Donor cells in the striatum of a four-week-old host, detected with an antibody to a human-specific nuclear antigen.
- FIG. 3G Extensive migration of transplanted cells from the aqueduct into the dorsal midbrain.
- FIG. 3H Human ES cell-derived neuron in the cortex of a two-week-old host, exhibiting a polar morphology and long processes. The cell is double labeled with antibodies to a human-specific nuclear marker
- Fig. 3J Donor-derived multipolar neuron, double labeled with an antibody recognizing the a and b isoforms of MAP2.
- Fig. 3K ES cell-derived astrocyte in the cortex of a four- week-old animal, double labeled with the human-specific nuclear marker (green) and an antibody to GFAP (red). Note that all the double labelings are confocal images
- Fig. 3C Fig. 3D 100 ⁇ m
- Fig. 3E Fig. 3F
- Fig. 4 Generation and regional specification of neuroectodermal cells.
- Fig. 4A Columnar cells appeared in the differentiating ES cell colony at day nine in the presence of 20 ng/ml of FGF2.
- Fig. 4B The columnar cells formed neural tubelike rosettes at day fourteen.
- Fig. 4C The cells in the rosettes with columnar morphology were positive for Sox1 (red).
- Fig. 4D The neural rosette cells in FGF2 treated cultures expressed Bf1 (red), but not En-1 (green).
- Fig. 4E The neural rosette cells in FGF2 treated cultures expressed Bf1 (red), but not En-1 (green).
- En-1 (green) expression was observed in the nestin 4" (red) neuroectodermal cells that were treated by six days with fibroblast growth factor 8 (FGF8) (100 ng/ml) at day nine, expanded in FGF8 for four days and then treated with sonic hedgehog (SHH) (200 ng/ml) for another six days on laminin substrate).
- FGF8 fibroblast growth factor 8
- SHH sonic hedgehog
- Fig. 5A Differentiation of DA neurons.
- Fig. 5B All TH + cells (red) in the culture were positively stained with a neuronal maker (green).
- Fig. 5C-E All TH + cells (d, green) in the culture were positively stained with aromatic acid decarboxylase (AADC) (d and e, red), but some AADC + cells were TH " (e, arrowheads).
- Fig. 5F Differentiation of DA neurons.
- Fig. 5A About one third of the differentiated cells were tyrosine hydroxylase (TH) positive in the cultures that were treated with FGF8, SHH and ascorbic acid (AA) at three weeks of differentiation.
- Fig. 5B All TH + cells (red) in the culture were positively stained with a neuronal maker (green).
- Fig. 5C-E All TH + cells (d, green) in the culture were positively stained with aromatic acid decarboxylase (AADC) (d and e, red), but
- TH + cells were negative for noradrenergic neuron marker dopamine /?-hydroxylase (D/?H) (green).
- the inset indicated that D ?H positively stained cells in the section of adult rat brain stem.
- Fig. 6A The differentiated DA neurons expressed genes characteristic of midbrain fate revealed by RT-PCR.
- EB embryoid body
- NE neuroectodermal cells
- 3w the DA culture differentiated for three weeks
- NC negative control.
- Fig. 6B The majority of TH + cells (red) in the cultures expressed midbrain marker En-1 (green).
- Fig. 6C GABA expressing cells (red) were present in the culture but very few TH + cells (green) co-expressed GABA (red, inset).
- Fig. 7A-C All TH + cells (a, green) expressed c-Ret (red).
- Fig. 7D-F. TH + cells (d, green) co-expressed VMAT2 (e and f; red).
- Fig. 8. Functional characteristics of the in vitro generated DA neurons.
- Fig. 8A Spontaneous and depolarization (56 mM KCI in HBSS)-induced DA release in the control and the treated cultures at three weeks of differentiation. Data were presented as means ⁇ SD from three experiments. *p ⁇ 0.05 vs. control by the unpaired student t test.
- Fig. 8B Action potentials evoked by depolarizing current steps (0.2 nA) in two neurons differentiated for thirty days. Passive membrane properties: (i) V rest -49 mV, C m 15.5 pF, R m 5.0 G ⁇ ; (ii) V res t-72 mV, C m 45 pF, R m 885 G ⁇ .
- Fig. 8C Passive membrane properties: (i) V rest -49 mV, C m 15.5 pF, R m 5.0 G ⁇ ; (ii) V res t-72 mV, C m 45 pF, R m 885 G ⁇ .
- Fig. 8C
- Fig. 9 Neuroectodermal cells induced by FGF2 display rostral phenotypes. ES cells, differentiated in FGF2 for ten days, displayed small, columnar morphology in the colony center, and organized into rosette formations. The columnar cells in the rosettes, but not the surrounding flat cells were positive for Pax6 and negative for Sox1 (A). By fourteen days, the columnar cells formed neural tube-like rosettes (B) and were positive for both Pax6 (C) and Sox1 (D).
- Fig. 10 Generation of motor neurons from neuroectodermal cells.
- FIG. 11 Effect of RA, FGF2 and SHH on neuroectodermal cells.
- RT-PCR analyses indicated changes of rostrocaudal genes from early rosettes cells that were cultured with RA or 20 ng/ml of FGF2 for one week in the neural induction medium.
- B Comparison of homeobox gene expression in early and late neuroectodermal cells treated with RA 0.1 ⁇ M for one week. The early neuroectodermal cells, treated with RA and then differentiated for twelve days, became mostly negative for Otx2 (C) but positive for HoxC8 (D). All the HoxC8 + cells were ?w-tubulin + (E). The Pax6-expressing neuroectodermal cells were negative for Olig2 (F).
- FIG. 12 Maturation of motor neurons in culture. ChAT-expressing cells were localized mainly in the cluster (A), and were large multipolar cells (B). Confocal image showed co-localization of ChAT in the soma and processes and HB9 in the nuclei in a three-week culture (C). Most cells in the cluster expressed VChAT (D). Many ChAT + cells were also positive for synapsin in somas and processes after five weeks in culture (E). (F) AP's evoked by depolarizing current steps (0.15 nA) in neurons maintained for 42 DIV. Resting membrane potential (Vm) -59 mV (fi) and -70 mV (fii).
- Fig. 13 Electrophysiological characterization of in vitro generated motoneurons.
- A AP's evoked by depolarizing current steps (0.15 nA) in neurons maintained for 42 DIV. Resting membrane potential (Vm) -59 mV (ai) and -70 mV (aii).
- B Spontaneous AP's in a neuron maintained for 42 DIV, Vm -50 mV.
- C Spontaneous inward and outward synaptic currents at - 0 mV using K-gluconate- based pipette solution under control conditions (ci).
- Applicants disclose a method of differentiating early rosettes (Pax6 + /Sox1 " ) from ES cells through an embryoid body intermediate. By differential treatment, Applicants can differentiate these early rosettes into three different forms of neural tube-like rosettes that are then suitable for development into forebrain dopamine neurons, midbrain dopamine neurons, or motor neurons.
- FGF8 Neural Tube- SHH Midbrain * Like Rosettes
- Dopamine 4-6d (Pax6+/Sox1+) Neurons En-1 + (midbrain)
- Neural Tube- SHH Forebrain 4-d 4-6d (Pax6+/Sox1-) 4-6d Like Rosettes
- Table 2 describes Phases 1 and 2 for generating dopamine and motor neurons. Table 2 also describes various intermediate products that Applicants consider to be markers of suitable development.
- this invention includes two main embodiments.
- One embodiment is the procedure for generating a synchronized population of neural stem cells (or neuroepithelial cells) in the form of neural tube-like rosettes and expression of neuroepithelial markers Pax ⁇ , Sox1 , nestin, Musashi-1.
- synchronize means a population of cells that are at the same developmental stage, as opposed to those induced by RA which results in heterogeneous differentiation, i.e., the culture contains cells in developmental stages from progenitors to differentiated neurons.
- the second embodiment is a method of further differentiation of the neuroepithelial cells to specialized neurons, such as midbrain dopamine neurons, forebrain dopamine neurons and spinal motor neurons.
- Table 3 below describes a preferred method of obtaining cells of the present invention.
- Table 3 includes both general culture broth components, that can be replaced by similar culture broths, and critical growth factor and timing components. When applicants refer to neural cell culture medium, many culture components are suitable. The sections below emphasize the culture components necessary for correct differentiation.
- a suitable medium is any medium used for growing neural cells.
- the following references (Bain, G., et al., supra. 1995; Okabe, S., et al., supra. 1996; Mujtaba, T., et al., supra. 1999; Housele, O., et J., supra. 1999; Zhang, S.-C, et aL, J. Neurosci. Res. 59:421-429, 2000; Zhang, S.-C, et a]., Proc. Natl. Acad. Sci. USA 96:4089-4094, 1999; Svendsen, C.N., et a]., Exp, Neurol.
- neuroepithelial cells neural stem cells
- the generation of neuroepithelial cells involves formation of embryoid bodies in suspension culture for 4-6 days, followed by adherent culture in the presence of growth factors, preferably FGF2 or FGF8, for 4-5 days when cells in the center of each colony become columnar and organize into a rosette form (Fig. 1 A, Fig. 4A, Fig. 9A, B).
- FGF4 and FGF9 are also suitable growth factors.
- the columnar cells in these rosettes express a neural transcription factor Pax6 but do not express another neural transcription factor Sox1 (Fig. 9C, D).
- Sox1 a neural transcription factor
- We call these rosettes "early rosettes” because they appear early and form by monolayer of columnar cells without a lumen. Every single colony possesses early rosettes. The total population of early rosette cells is at least 70% of the total cells.
- Further culture of these early rosettes for 4-6 days will lead to formation of neural tube-like rosettes (Fig. 1 B, Fig. 4B, Fig. 9E).
- the neural tube-like rosettes are formed by multiple layers of columnar cells with a clear lumen.
- the cells in the rosettes express Sox1 in addition to Pax6 (Fig. 4C, Fig.
- the functional significance of these cells is relevant to the present invention in that the Pax6+/Sox1- neuroepithelial cells in the early rosettes, but not the Pax6+/Sox1+ neuroepithelial cells in the neural tube-like rosettes, can be efficiently induced to become neurons carrying positional identities other than forebrain such as midbrain dopamine neurons and spinal motor neurons (Table 1 , see above).
- the neuroepithelial cells represent at least 70-90% of the total differentiated cells.
- the neuroepithelial cells in the form of neural tube-like rosettes can be purified through treatment with a low concentration of dispase and differential adhesion (described in U.S. Serial No. 09/960,382). 2. Generation of midbrain dopamine neurons
- a functional neuron with potential therapeutic application must possess at least two additional characteristics in addition to being a neuron: a specific positional identity and the capacity to synthesize, release, and uptake a neural transmitter.
- the first step in generating midbrain dopamine neurons is the induction of a midbrain identity.
- Pax6 + /Sox1 + neural tube-like rosette cells results in efficient differentiation of the cells to progenitors that express midbrain transcription factors Engrailed 1 (En-1) and Pax 2 (Fig. 4E, F) and down regulation of forebrain marker Bf-1 (Fig. 4D).
- the second step is to culture the midbrain progenitors in the presence of sonic hedgehog (SHH, 50-250 ng/ml) for 6-7 days, then in the regular neuronal differentiation medium (such as that described in Table 3) for additional 2 weeks until dopamine neurons develop.
- SHH sonic hedgehog
- the regular neuronal differentiation medium such as that described in Table 3
- at least 35% of the total differentiated cells will become dopamine neurons.
- a preferred differentiation medium is described in Table 3.
- the dopamine neurons express TH, AADC, but not DbH and PNMT
- the dopamine neurons express En-1 , ptx3, Nurrl , and Lmx1 b (Fig.
- the dopamine neurons do not express GABA (Fig. 6C). Coexpression with GABA is the feature of dopamine neurons in the olfactory bulb. [0048] The dopamine neurons do not express calbindin (Fig. 6D).
- Coexpression with calbindin is the feature of dopamine neurons in the tegamental area of the midbrain.
- the dopamine neurons generated in our culture system are midbrain dopamine neurons, more closely resembling those in the substantial nigra, the dopamine neurons that are lost in Parkinson's disease.
- the dopamine neurons also express VMAT2 (Fig. 7D, E, F), a transporter required for storage and release dopamine. They also express DAT (Fig. 7G, H, I), a transporter necessary for dopamine uptake after release.
- VMAT2 Fig. 7D, E, F
- DAT Fig. 7G, H, I
- the dopamine neurons express synaptophysin (Fig. 7) for formation of synapses. They can fire action potentials and can secrete dopamine in response to stimulation (Fig. 8). Therefore, the dopamine neurons are functional.
- the first step in generating spinal motor neurons is the induction of a spinal cord (caudal) identity.
- Treatment of the Pax6+/Sox1- early rosette cells, but not the Pax6+/Sox1+ neural tube-like rosette cells (Fig. 10A), with RA (0.001-1 uM) for 6-7 days results in efficient differentiation of the cells to progenitors that express spinal cord transcription factor Hox genes such as HoxB1 , HoxB6, HoxC5, HoxC8, but not forebrain markers Otx2 and Bf-1 or midbrain marker En-1 (Fig.
- the second step is to culture the spinal cord progenitors in the presence of sonic hedgehog (SHH, 50-250 ng/ml) for 6-7 days to induce a ventralized progenitor character, as evidenced by expression of Olig2, (Fig. 11 F, G,
- a preferred differentiation medium is described in Table 3.
- At least 22% of the total differentiated cells become spinal motor neurons.
- the motor neurons express HB9, islet1/2, and Lim3
- Fig. 10 transcription factors that are specifically expressed by spinal cord motor neurons.
- the motor neurons also express HoxB1 , HoxB6, HoxC5, HoxC ⁇ , but not forebrain markers Otx2 and Bf-1 or midbrain marker En-1 (Fig. 11 A, C, D, E), indicating that they are spinal motor neurons.
- the motor neurons express ChAT (Fig. 12A, ⁇ , C, D), an enzyme necessary for synthesizing the motor neuron transmitter acetylcholine.
- the motor neurons also express VAChT (Fig. 12E), suggesting that the motor neuron can store and uptake the transmitter acetylcholine.
- the motor neurons express synapsin (Fig. 12F) for formation of synapses. They can fire action potentials (Fig. 13). Therefore, the motor neurons are functional. We have data showing that the motor neurons release acetycholine, as analyzed by HPLC.
- the present invention is a method of differentiating primate ES cells (preferably human ES cells) into forebrain dopamine neurons, preferably transplantable neural precursors suitable for nervous system repair.
- primate ES cells preferably human ES cells
- forebrain dopamine neurons preferably transplantable neural precursors suitable for nervous system repair.
- the Pax6 + /Sox1 " cells are treated for an additional 4 - 6 days with FGF2 and are then treated with SHH.
- the steps in generating forebrain dopamine neurons and the analyses for determining the dopamine neuron characters are similar to those described for midbrain dopamine neurons. The main difference is the use of morphogens at a particular period and the features of dopamine neurons.
- the first step in generating forebrain dopamine neurons is the induction of a midbrain identity.
- Treatment of the Pax6+/Sox1- early rosette cells with FGF2 (10-20 ng/ml) for 6 - 7 days results in efficient differentiation of the cells to progenitors that express forebrain transcription factors Bf-1 and Otx2.
- the second step is to culture the forebrain progenitors in the presence of sonic hedgehog (SHH, 50-250 ng/ml) for 6 - 7 days, then in the regular neuronal differentiation medium for additional 2 weeks until dopamine neurons develop. 35% of the total differentiated cells become dopamine neurons.
- SHH sonic hedgehog
- a primate ES cell line preferably a human ES cell line, is first obtained and propagated.
- the embryonic stem cell line will also retain the ability, throughout the culture, to form trophoblasts and to differentiate into tissue derived from all three embryonic germ layers (endoderm, mesoderm and ectoderm).
- the cells are then cultured.
- the cells are propagated on a feeder layer of irradiated mammalian, preferably mouse, embryonic fibroblasts, preferably as disclosed below and in Thomson, J.A., et a]., supra. 1998 and U.S. Patent Nos. 5,843,780 and 6,200,806.
- a feeder layer of irradiated mammalian, preferably mouse, embryonic fibroblasts, preferably as disclosed below and in Thomson, J.A., et a]., supra. 1998 and U.S. Patent Nos. 5,843,780 and 6,200,806.
- the ES cell colonies are typically removed intact from adherent cultures by treatment with dispase and grown in a suspension as free-floating ES cell aggregates called embryoid bodies (EBs), preferably for four days as described below.
- EBs embryoid bodies
- the EBs are then cultured in medium containing FGF2, preferably at
- a suitable medium is any medium used for growing neural cells.
- the following references (Bain, G., et al., supra, 1995; Okabe, S., et a]., supra. 1996; Mujtaba, T., et al., supra. 1999; Housele, O., et al., supra. 1999; Zhang, S.-C, et a]., j ⁇ Neurosci. Res. 59:421-429, 2000; Zhang, S.-C, et a]., Proc. Natl. Acad. Sci.
- neural precursors may confirm the presence of neural precursors by morphology or by immunofluorescence analysis using neural marker antigens such as nestin and Musashi I, as described below.
- the neural precursors comprise at least 72%, and most preferably at least 84%, of the total cells.
- treatment with dispase will lead to the preferential detachment of the central neuroepithelial islands.
- the differentiating EBs cultured for eight to ten days are preferably incubated with 0.1-0.2 mg/ml dispase (Gibco BRL, Lifetechnologies, Rockville, MD) at 37°C for 15-20 minutes. Alternatively, 0.2 mg/ml of dispase may be used. The rosette clumps retract whereas the surrounding flat cells remain adherent.
- the rosette clumps may be dislodged by swaying the flask, which leaves the flat cells adherent.
- the clumps are pelleted, gently triturated with a 5 ml pipette and plated into a culture flask for 30 minutes to allow the contaminating individual cells to adhere.
- the floating rosette clumps are then transferred to a new flask, preferably coated with poly-(2-hydroxyethyl-methacrylate) to prohibit attachment, and cultured in a medium used for human neural precursors with the presence of FGF2 (typically 20 ng/ml).
- Neural precursor cells typically comprise at least 72-84% of the total cells.
- the present invention is a cell population comprising at least 72%, and preferably 84%, neural precursor cells. These neural precursor cells can be defined by being nestin and Musashi I positive.
- Fig. 1 B illustrates the rosette formation characterizing these cells. By rosette formation, we mean that cells are columnar in shape and are arranged in a tubular (rosette) structure, resembling the neural tube (developing brain) in the body. The columnar cell morphology and tubular structures are shown in the insert of Fig. 1B.
- the present invention is a cell population of at least 90% and preferably at least 96% neural precursor cells. One would preferably obtain these cells after differential enzymatic treatment and adhesion, as described below in the Examples.
- the described system can be readily modified to mimic pathological processes that lead to death of dopamine neurons (such as in Parkinson's disease) or motor neurons (such as in ALS), which may be effectively used to screen therapeutic agents that are designed to treat these diseases.
- dopamine neurons such as in Parkinson's disease
- motor neurons such as in ALS
- the described system can be readily modified to mimic pathological processes that lead to death of dopamine neurons (such as in Parkinson's disease) or motor neurons (such as in ALS), which may be effectively used to screen therapeutic agents that are designed to treat these diseases.
- dopamine neurons such as in Parkinson's disease
- motor neurons such as in ALS
- Human ES cells differentiate to form neural tube-like structures in the presence of FGF2.
- Human ES cell lines, H1 , H9 and a clonal line derived from H9, H9.2 were propagated on a feeder layer of irradiated mouse embryonic fibroblasts (Thomson, J. A., et al., supra, 1998).
- ES cell colonies were detached and grown in suspension as embryoid bodies (EBs) for four days. The EBs were then cultured in a tissue culture treated flask in a chemically defined medium (Zhang, S.-C, et al., J. Neurosci. Res.
- FGF2 was obtained from Peprotech, Inc., Rocky Hill, NJ. After five days of culture in FGF2, the plated EBs had generated an outgrowth of flattened cells. At the same time, an increasing number of small elongated cells was noted in the center of the differentiating EBs (Fig. 1 A). By seven days in the defined medium, the central, small, elongated cells had generated rosette formations (Fig. 1 B) resembling the early neural tube as shown by toluidine blue-stained sections (inset in Fig. 1 B).
- Neural tube-like rosettes can be isolated by differential enzymatic treatment and adhesion. With continued exposure to FGF2, the columnar rosette cells expanded and formed multiple layers. They frequently made up most of the EB and were sharply demarcated from the surrounding flat cells. Treatment with dispase led to the preferential detachment of the central neuroepithelial islands, leaving the surrounding cells largely adherent (Fig. 1 F). Contaminating single cells were separated by short-term adhesion to cell culture dishes. Cell counts performed immediately after this isolation and enrichment procedure showed that cells associated with the isolated neuroepithelial clusters made up 72-84% of the cells in the differentiated EB cultures.
- Human ES cell-derived neural precursors generate all three CNS cell types in vitro.
- the isolated neural precursors were expanded as free-floating cell aggregates in a suspension culture, similar to "neurosphere" cultures derived from human fetal brain tissues (Zhang, S.-C, et al., supra, 2000; Svendsen, C.N., et a ., supra, 1996; Carpenter, M.K., et al., supra, 1999; Vescovi, A.L., et al., supra, 1999).
- BrdU incorporation studies revealed that stimulation of precursor cell proliferation was dependent on FGF2 and could not be elicited by either EGF or LIF alone.
- NF high molecular weight NF was observed by seven to ten and ten to fourteen days after plating, respectively (Fig. 2D).
- Antibodies to various neurotransmitters were used to further characterize the ES cell-derived neurons. While the majority of the neurons exhibited a glutamatergic phenotype (Fig. 2E), a smaller proportion was labeled with an antibody to GABA. Frequently, these neurons showed a polar morphology (Fig. 2F). A small number of neurons were found to express TH (Fig. 2G), the rate-limiting enzyme for dopamine synthesis. GFAP + astrocytes were rarely found within the first two weeks after growth factor withdrawal (Fig. 2C), but became more frequent after prolonged in vitro differentiation.
- ES cell-derived neural precursors generate all three major cell types of the CNS.
- Human ES cell-derived neural precursors migrate, incorporate, and differentiate in vivo.
- DNA in situ hybridization with a human-specific probe and immunohistochemical detection of a human nucleus-specific antigen revealed the presence of grafted cells in numerous brain regions. Gray matter areas exhibiting widespread donor cell incorporation included cortex (Fig. 3A), hippocampus (Fig. 3B,C), olfactory bulb, septum (Fig. 3D), thalamus, hypothalamus (Fig. 3E), striatum (Fig. 3F) and midbrain (Fig. 3G).
- Fig. 3H, J Frequently, they displayed polar morphologies with long processes (Fig. 3H).
- Fig. 3J neurons with multipolar and immature unipolar morphologies were found (Fig. 3J).
- the donor-derived neurons generated numerous axons projecting long distances into the host brain, which were detected in both gray and white matter. They were particularly abundant within fiber tracts such as the corpus callosum, the anterior commissure and the fimbria hippocampi where they could frequently be traced for several hundred micrometers within a single section (Fig. 31).
- a small number of ES cell-derived astrocytes was detected within the host brain tissue.
- ES cells Exploiting growth factor-mediated proliferation/differentiation and differential adhesion of neural precursor cells, the in vitro differentiation procedure described herein provides a new platform for the study of neural development and the generation of donor cells for nervous system repair.
- a key finding of this study is the observation that the differentiation of neural precursors from human ES cells appears to recapitulate early steps of nervous system development with the formation of neural tube-like structures in vitro. This phenomenon can now be exploited to study and experimentally manipulate the initial stages of human neural development under controlled conditions.
- the chemically defined culture system provides a unique opportunity to explore the effects of single factors on human neuroepithelial proliferation and specification in vitro. Similar to precursors derived from the developing human brain, human ES cell-derived precursors show a strong proliferative response to FGF2 (Flax, J.D., et al., supra, 1998). However, no additive or synergistic effects on proliferation can be elicited by EGF or LIF.
- the ES cell- derived neural precursors Following transplantation into the neonatal mouse brain, the ES cell- derived neural precursors incorporated into a large variety of brain regions where they differentiated into neurons and glia.
- the failure to detect mature oligodendrocytes in vivo is likely due to the low oligodendroglial differentiation efficiency of human neural precursors as opposed to their rodent counterparts (Svendsen, C.N., et al.. Brain Pathol. 9:499-513. 1999).
- donor-derived neurons were not restricted to sites exhibiting postnatal neurogenesis but were also found in many other regions of the brain. Similar data were obtained in studies involving transplantation of human CNS-derived precursors into the adult rodent brain (Tropepe, V.. et al..
- ES cells were cultured on a feeder layer of irradiated mouse embryonic fibroblasts with a daily change of a medium that consisted of Dulbecco's modified Eagle's medium
- DMEM fetal calf serum
- Gibco serum replacement
- 0.1 mM ⁇ -mercaptoethanol 2 ⁇ g/ml
- ES cell cultures were incubated with dispase (Gibco BRL, 0.1 mg/ml) at 37°C for 30 minutes, which removed ES cell colonies intact.
- the ES cell colonies were pelleted, resuspended in ES cell medium without FGF2, and cultured for four days in a 25-cm 2 tissue culture flask (Nunc) with a daily medium change.
- ES cell colonies grew as floating EBs whereas any remaining feeder cells adhered to the flask.
- the feeder cells were removed by transferring the EBs into a new flask. EBs ( ⁇ 50/flask) were then plated in a 25-cm 2
- tissue culture flask (Nunc) in DMEM/F12, supplemented with insulin (25 ⁇ g/ml),
- transferrin 100 ⁇ g/ml
- progesterone 20 nM
- putrescine 60 ⁇ M
- Isolation and culture of neural precursor cells To separate the clusters of rosette cells from the surrounding flat cells, the cultures were incubated with 0.1 mg/ml dispase at 37°C for 15-20 minutes. The rosette clumps retracted whereas the surrounding flat cells remained adherent. At this point, the rosette clumps were dislodged by swaying the flask, which left the flat cells adherent. The clumps were pelleted, gently triturated with a 5-ml pipette and plated into a culture flask for 30 minutes to allow the contaminating individual cells to adhere.
- the floating rosette clumps were then transferred to a new flask coated with poly-(2-hydroxyethyl- methacrylate) to prohibit attachment and cultured in a medium used for human neural precursors (Zhang, S.-C, et al., supra, 2000) with the presence of FGF2 (20 ng/ml).
- a medium used for human neural precursors Zhang, S.-C, et al., supra, 2000
- FGF2 20 ng/ml
- freshly separated cell clusters and the flat cells left behind were dissociated with trypsin (0.025% in 0.1% EDTA) and counted.
- the percentage of putative neural precursors (rosette cells) among the total cells differentiated from ES cells was obtained based on 3 independent experiments on H9 and H9.2 lines.
- ES cell-derived neural precursors For analyses of the differentiation potential of the ES cell-derived neural precursors, cells were cultured on ornithine/laminin substrate in a medium consisting of DMEM/F12, N2 supplement (Gibco), cAMP (100 ng/ml), and BDNF (10 ng/ml, PeproTech) without the presence of FGF2.
- DMEM/F12 N2 supplement
- cAMP 100 ng/ml
- BDNF 10 ng/ml, PeproTech
- anti-GFAP polyclonal, Dako, 1 :1 ,000
- anti-human GFAP Sternberg monoclonals, 1 :10,000
- O4 mouse IgM, hybridoma supernatant, 1 :50
- anti-tyrosine hydroxylase TH, Pel Freez, 1 :500.
- NF neurofilament 68 (mouse IgG, 1 :1 ,000); anti-NF 200 (polyclonal, 1 :5,000); anti-NF 68 (mouse IgG, 1 :1 ,000); anti-NF 200 (polyclonal, 1 :5,000); anti-NF 68 (mouse IgG, 1 :1 ,000); anti-NF 200 (polyclonal, 1 :5,000); anti-
- MAP2ab mouse IgG, 1 :250
- GABA anti- ⁇ -aminobutyric acid
- mice were perfused transcardially with Ringer's followed by 4% paraformaldehyde. Brains were dissected and post-fixed in the same fixative at 4°C until use. Donor cells were identified in 50- ⁇ m coronal vibratome-sections by in situ
- MAP2ab Sigma, clones AP-20 and HM-2, 1 :300
- phosphorylated medium molecular weight human neurofilament (clone HO-14, 1 :50, a gift of J. Trojanowski).
- Primary antibodies were detected by appropriate fluorophore- conjugated secondary antibodies. Sections were analyzed on Zeiss Axioskop 2 and Leica laser scan microscopes.
- a first step toward potential application of stem cell therapy in neurological conditions is the directed differentiation of neural cells with correct positional and transmitter phenotypes.
- DA dopaminergic
- ES human embryonic stem
- FGF8 treatment of human ES-derived neuroectodermal cells at an early stage, before the expression of Sox1 , with FGF8 is essential for specification of DA neurons with correct midbrain DA projection neuronal phenotypes.
- the in vitro generated DA neurons may be used for toxicological and pharmaceutical screening and for potential cell therapy in
- Parkinsons' disease results from progressive degeneration of DA neurons in the midbrain, especially the substantia nigra.
- Current therapy for PD relies primarily on symptom relief by systemic administration of DA precursors such as levadopa. Such therapy is effective for the first few years but almost invariably loses its efficacy and produces serious side effects.
- Administration of growth factors such as glial cell line-derived neurotrophic factor (GDNF) has been shown to be effective in a small clinical trial (Gill, S.S., et aj., Nat Med. 9:589-595, 2003). This therapy would depend on a sufficient number of surviving DA neurons, and its long- term therapeutic potential remains to be investigated.
- GDNF glial cell line-derived neurotrophic factor
- DA neurons can be efficiently generated from mouse ES cells, which are derived from the inner cell mass of pre-implantation embryos at the blastocyst stage (Evans, M.J. and Kaufman, M.H., Nature 292:154- 156, 1981 ; Martin, G.R., Proc. Natl. Acad. Sci. USA 78:7634-7638, 1981 ).
- Mouse ES cells are first induced to neuroectodermal cells by FGF2 (Lee, S.H., et aj., Nat- Biotech nol.
- ES cell colonies detached from a feeder layer, were cultured in suspension as aggregates for four days in ES cell growth medium, and then grown in an adhesive culture dish in a chemically defined neural medium containing FGF2
- FGF8 For differentiation to DA neurons, neuroectodermal cells in the neural tube-like rosettes were enriched through differential enzymatic and adhesion treatment (Zhang, S.C, et al., supra, 2001 ), expanded for four days as aggregates in suspension with FGF2, and were then plated onto a laminin substrate and treated with SHH (50-200 ng/ml) and FGF8 (20-100 ng/ml) for six days. Immunocytochemical analyses revealed that the vast majority of the neuroectodermal cells remained positive for Bfl but not for En-1 (not shown). [0097] The failure of FGF8 to induce Sox1 + neuroectodermal cells to express
- Sox1 -expressing neuroectodermal cells may be refractory to patterning signals. Since the Sox1 -expressing cells are generated two weeks after differentiation of human ES cells (equivalent to a six-day-old embryo (Thomson, J.A., et aj., supra, 1998)) and formed neural tube-like structures, they may correspond to the neuroectodermal cells at neural tube closure during which neuroectodermal cells express Sox1 and are regionally specified (Lumsden, A. and Krumlauf, R.. Science 274:1109-1115, 1996). This led us to hypothesize that FGF8 may promote midbrain specification before neuroectodermal cells express Sox1.
- FGF8 100 ng/ml
- Regionalized neuroectodermal cells differentiate into DA neurons [0098] The neuroectodermal cells were dissociated and differentiated in a neural differentiation medium. They did not express stage specific embryonic antigen 4 (SSEA4), a glycoprotein highly expressed by undifferentiated human ES cells. The disaggregated neuroectodermal cells, initially distributed evenly, reformed rosettes three to five days after plating. They then extended processes and exhibited polar morphology. At three weeks after differentiation, about one third of the total differentiated cell population (31.8 ⁇ 3.1 % TH + cells of 17,965 cells counted from four experiments) were positive for tyrosine hydroxylase (TH) (Fig. 5A).
- SSEA4 stage specific embryonic antigen 4
- TH + cells were 10-20 ⁇ m in diameter. They exhibited multipolar morphology, with differentiable axons and dendrites (Fig. 5A). All the TH + cells were stained positively with a neuronal marker ? ⁇ n-tubulin + neurons, about 50% were TH + (Fig. 5B, 6,383 TH + cells of 12,859 #n-tubulin + neurons from four experiments).
- DOPA which is subsequently decarboxylated to become DA by AADC.
- D ?H and phenylethanolamine N-methyltransferase (PNMT) transform DA to norepinephrine and catalyze norepinephrine to epinephrine, respectively.
- PNMT phenylethanolamine N-methyltransferase
- Immunostaining showed that all TH + cells were AADC (Fig. 5C-E) although some AADC + cells were negative for TH (Fig. 5E).
- TH + cells were negative for D ⁇ H (Fig. 5F) and PNMT (not shown), although D ?H strongly stained noradrenergic neurons in the adult rat and embryonic monkey brainstem (inset in Fig. 5F).
- ES cell-generated DA neurons display midbrain phenotypes [00100]
- RT-PCR analyses indicated that Nu ⁇ , Limxl b, En-1 and Ptx3, which are involved in midbrain DA neuron development (Zetterstrom, R.H., et al., Science 276:248-250, 1997; Smidt, M.P.. et al.. Proc. Natl. Acad. Sci. USA 94:13305-13310, 1997; Saucedo-Cardenas, O., et aj., Proc. Natl. Acad. Sci.
- DA neurons generated using the above approach possess a midbrain positional identity.
- DA neurons in the olfactory bulb often co-express -arninobutyric acid
- GABA GABA
- Double immunostaining of TH and GABA indicated that most of the DA neurons were negative for GABA although GABA* neurons were found in the culture (Fig. 6C).
- TH + cells 8% (8.7 ⁇ 3.9%, 6,520 TH + cells counted from four experiments) of TH + cell co-expressed GABA. Most of these double positive cells were small bipolar cells (inset in Fig. 6C).
- Some midbrain DA neurons especially those in the ventral tegmental area, co-express cholecystokinin octapeptide (CCK8) or calbindin along with TH (McRitchie, D.A., et al.. J. Comp. Neurol. 364:121-150, 1996; Hokfelt. T.. et al.. Neurosci. 5:2093-2124. 1980).
- Immunohistochemical analyses indicated that the TH + neurons were observed (Fig. 6D). These calbindin neurons were mostly small cells. No CCK8 positive cells were detected in the cultures.
- ES cell-generated DA neurons are biologically functional
- Immunostaining showed that all TH + neurons expressed c-Ret, a component of the receptor for GDNF (Fig. 7A-C).
- the majority of the TH + cells especially those with branched neurites, expressed vesicular monoamine transporter 2 (VMAT2, Fig. 7D-F), which is responsible for packaging dopamine into subcellular compartments in monoamine neurons (Nirenberg, M.J., et al., J. Neurosci. 16:4135- 4145, 1996).
- TH + neurons expressed synaptophysin, a membrane glycoprotein essential to synapse formation (Calakos, N. and Scheller, R.H., J. Biol. Chem. 269:24534-24537. 1994) (Fig. 7A-I).
- Dopamine release is a functional hallmark of DA neurons.
- High performance liquid chromatography (HPLC) analyses revealed the presence of dopamine in the medium of DA differentiation cultures, with 230.8 ⁇ 44.0 pg/ml in the cultures treated with ascorbic acid (AA), FGF8 and SHH and 46.3 ⁇ 9.2 pg/ml in the control cultures without the treatment of AA, FGF8 and SHH (Fig. 8A).
- AA ascorbic acid
- FGF8 and SHH 46.3 ⁇ 9.2 pg/ml in the control cultures without the treatment of AA, FGF8 and SHH
- Action potential (AP) threshold ranged from -26 to -5.2 mV (-17.4 ⁇ 2.1 mV), and peaked at -9.6 to 30 mV.
- AP's up to 50.2 mV were observed (32 ⁇ 2.8 mV).
- AP duration ranged from 3 to 20.6 ms (7.2 ⁇ 1.3 ms).
- Spontaneous firing was observed in two cells (Fig. 8C).
- In voltage clamp mode both inward and outward currents were observed in all cells (not shown), but their relative magnitudes varied considerably. Inward currents were activated rapidly ( ⁇ 1 ms), and peaked within 1-3 ms.
- TTX tetrodotoxin
- DA neurons with midbrain neuronal projection characteristics can be efficiently generated from human ES cells through three simple non-genetic steps: induction of neuroectodermal cells with FGF2, specification of ventral midbrain identity by FGF8 and SHH during neuroectodermal formation, and differentiation of the regionally specified progenitors to DA neurons.
- induction of neuroectodermal cells with FGF2 specification of ventral midbrain identity by FGF8 and SHH during neuroectodermal formation
- differentiation of the regionally specified progenitors to DA neurons Unlike the findings obtained from mouse ES cell studies in which DA neurons with midbrain characteristics can be generated from expanded neuroectodermal cells (Lee, S.H., et aj., supra. 2000), we have found that specification or regionalization with FGF8 before precursor cells become Sox1 + neuroectodermal cells is essential for a robust generation of human DA neurons with correct midbrain and functional phenotypes.
- the projection neurons including midbrain DA neurons, are differentiated from neuroectodermal cells in the neural tube at the early stage and these neuroectodermal cells are already regionally specified during the process of neural tube closure (Lumsden, A. and Krumlauf, R., supra. 1996). This may explain why the human ES cell-generated Sox1 -expressing neuroectodermal cells that possess forebrain phenotypes are not responsive to morphogens for generating DA neurons with midbrain phenotypes.
- FGF8 may instruct the early precursors to adopt a midbrain identify is confirmed by the generation of DA neurons that have characteristics of projection neurons such as large cell bodies with complex processes and expression of midbrain makers En1 , after the Sox1 " columnar cells in the early rosettes are treated with FGF8.
- DA neurons are present in several areas of the brain, including midbrain, hypothalamus, retina, and olfactory bulbs.
- the human ES cell-generated DA neurons in this study resemble midbrain projection DA neurons.
- Most of the DA neurons do not co-express GABA, whereas co-expression of GABA and TH is a major feature of olfactory DA interneurons (Kosaka, T., et aj., supra, 18987; Gall, CM., et al., supra. 1987).
- DA neurons In the midbrain, there are at least two major groups of DA neurons, those in the substantia nigra (A9) and in the ventral tegmental area (A10), each having different targets (Bjorklund, A. and Lindvall, O., Handbook of Chemical Neuroanatomy, Vol. 2: Classical Transmitters in the CNS (Bjorklund, A., Hokfelt, T., eds), Amsterdam, Elsevier Science Publishers, pp. 55-111 , 1984). Most DA neurons in the ventral tegmental area express calbindin or CCK, whereas few in the substantial nigra do (McRitchie, DA. et al.. J. Comp. Neurol.
- ES cell cultures Human ES cell lines, H9 (p21-56) and H1 (p35-40), were propagated weekly on irradiated mouse embryonic fibroblasts (MEF) with a daily change of an ES cell growth medium that consisted of Dulbecco's modified Eagle's medium (DMEM)/F12 (Gibco), 20% serum replacer (Gibco), 1 mM glutamine (Sigma), 0.1 mM non-essential amino acids (Gibco), 2 ⁇ g/ml of heparin (Sigma), 0.1 mM S-mercaptoethanol (sigma), and 4 ng/ml of FGF2 (R & D Systems), as described by Thomson (Thomson, J.A., et al., supra, 1998).
- DMEM Dulbecco's modified Eagle's medium
- F12 serum replacer
- 1 mM glutamine Sigma
- 0.1 mM non-essential amino acids Gibco
- a neural medium consisting of DMEM/F12 (2:1), supplemented with N2 (Gibco), 0.1 mM non-essential amino acids, 2 ⁇ g/ml heparin with a medium change every other day.
- the ES cell aggregates attached and formed individual colonies at around day six.
- Neuroectodermal cells exhibited by columnar cells organizing into neural tube-like rosettes, were developed at around day fourteen (Zhang, S.C, et al., supra, 2001 ).
- the neural rosettes were isolated through differential enzymatic response (Zhang, S.C, et al., supra, 2001). Growth factors were added during the course of differentiation to influence regionalization (see results).
- DA neuron differentiation The enriched neuroectodermal cells were dissociated by 0.025% trypsin and 0.27 mM EDTA in PBS at 37°C for 10-15 minutes and plated onto 12-mm coverslips (pre-coated with 100 ⁇ g/ml polyomithine and 10 ⁇ g/ml laminin) at a density of 40,000-50,000 cells/coverslip.
- the neuronal differentiation medium consisted of neurobasal medium (Gibco) supplemented with N2, 0.1 mM non-essential amino acids, 0.5 mM glutamine, 1 ⁇ g/ml laminin, 1 ⁇ M cAMP, 200 ⁇ M AA (Sigma), 10 ng/ml BDNF (R & D Systems) and 10 ng/ml GDNF (R & D Systems).
- the cells were cultured for three to four weeks with medium change every other day.
- mouse anti-SSEA4 (1 :40), mouse anti-En-1 (1 :50) and mouse anti-Pax6 (1 :5000, all from Developmental studies hybridoma bank
- rabbit anti-Sox 1 (1 :500), rabbit anti-human nestin (1 :200), rabbit anti-AADC (1 :1000), sheep anti D ⁇ H, (1 :400), mouse anti-synaptophysin (1 :500) and rabbit anti-CCK8 (1 :2000, all from Chemicon
- mouse anti-TH (1 :1000), mouse anti- ⁇ lll tubulin (1 :500), rabbit anti-GABA (1 :5000) and mouse anti-calbindin (1:400, all from Sigma
- Goat anti-c-Ret (1 :400) and mouse anti-Oct4 (1 : 1000, both from Santa Cruz
- rabbit anti-Bfl (1 :5000; gift from Lorenz Studer
- Antibody-antigen reaction was revealed by appropriate fluorescence-conjugated secondary antibody.
- Cell nuclei were stained with Hoechst 33342. Staining was visualized with a Nikon fluorescence microscope. Brain sections from adult rats and E38 embryonic monkeys were used as positive controls for many of the antibodies against neuronal types and neurotransmitters. Negative controls were also set by omitting the primary or secondary antibodies in the immunostaining procedures.
- Cell counting was achieved blindly by using a reticule on eyepiece and a 40x objective. The cells in ten visual fields were randomly selected and counted from each coverslip.
- Negative control was achieved by omitting transcriptase during reverse transcription or cDNA sample during PCR.
- the primers and product lengths were as follows: GAPDH (5'-ACCACAGTCCATGCCATCAC-3 ⁇ 5'-TCCACCACCCTGTTGCTGTA-3', 450 bp); Nurrl (5'-
- En-1 (5'-CCCTGGTTTCTCTGGGACTT-3', 5'-GCAGTCTGTGGGGTCGTATT-3', 162 bp).
- HBSS Hank's balanced salt solution
- Electrophysiological properties of the DA neurons differentiated from human ES cells were investigated using whole-cell patch-clamp recording technigues (Hammill, P.P.. et al.. Pflugers Arch. 391 :85-100, 1981 ). Pipettes were filled with intracellular solutions containing (mM) KC1 140 or K-gluconate 140, Na + - HEPES 10, BAPTA 10, Mg 2+ -ATP 4, (pH 7.2, 290 mOsm, 2.3-5.0 M ⁇ ). Biocytin (0.5%, Sigma) was added to the recording solution and subsequent labeling with streptavidin-Alex Flur 488 (1 : 1000, Molecular Probes) and an antibody against TH was used to identify DA neurons.
- the bath solution contained (in mM) NaC1 127, KH 2 PO 4 1.2, KCI 1.9, NaHCO 3 26, CaCI 2 2.2, MgSO 4 1.4, glucose 10, 95% O 2 /5% CO 2 (pH 7.3, 300 mOsm).
- TTX (1 ⁇ m) was applied in the bath solution to block voltage-gated sodium currents.
- Synaptic events were detected using a template detection algorithm (Mini Analysis Program 4.6.28, Synaptosoft) and deactivation phase was fitted to a biexponential function using the Levenberg-Marquardt algorithm. Data are presented as mean ⁇ SE.
- Generation of motor neurons in vertebrate animals involves at least three steps: neuralization of ectodermal cells, caudalization of the neuroectodermal cells, and ventralization of the caudalized neural progenitors (Jessell, T.M., Nat. Rev.
- the first sign of neural differentiation was the appearance of columnar cells forming rosettes in the center of colonies 8-10 days after ES cells were removed from feeder cells for differentiation.
- Soxl (Fig. 9A), which is expressed by neuroepithelial cells during neural tube formation (Pevny, L.H., et al., Development 125:1967-1978, 1998). With further culturing in the same medium for another four to five days, the columnar cells organized into neural tube-like rosettes with lumens (Fig. 9B) and expressed both
- Pax6 and Sox1 (Fig. 9C, D).
- differentiation of neuroectodermal cells from hES cells involves at least two distinctive stages, the Pax6 + /Sox1 " columnar cells in the early rosettes eight to ten days after neural induction, and the Pax6 + /Sox1 + cells forming neural tube-like late rosettes fourteen days after induction.
- Immunocytochemical analyses revealed that the rosette cells, which expressed Pax6 (Fig. 9E), Sox1 , and nestin, were positive for Otx2 (Fig. 9F, H), a homeodomain protein expressed by fore- and mid-brain cells; but negative for HoxC8 (Fig. 9H), a homeodomain protein produced by cells in the spinal cord.
- retinoic acid RA, 0.001-1 ⁇ M
- caudalizing reagent Blumberg, B., et al., Development 124:373-379, 1997)
- SHH 50-500 ng/ml
- a ventralizing morphogen Jessell, T.M., Nat. Rev. Genet. 1 :20-29, 2000; Briscoe, J. and Ericson, J.. Curr. Opin. Neurobiol. 11 :43-49. 2001 ).
- the Sox1 -expressing cells may correspond to neuroectodermal cells in the neural tube given the formation of neural tube-like rosettes and expression of Sox1 at a time equivalent to a three-week-old human embryo.
- the neuroectodermal cells in the neural tube are regionally specified (Lumsden, A. and Krumlauf, R., Science 274:1109-1115, 1996). This consideration led us to hypothesize that RA may promote caudalization and/or motor neuron specification before neuroectodermal cells express Sox1.
- RA 0.001-1 ⁇ M
- HB9-expressing cells first appeared at day six and reached a high proportion around day ten to twelve after the neural rosettes were plated for differentiation. They were largely localized to the cluster, with about 21 % of the total cells in the cluster and few cells in the outgrowth area (Fig. 10A, D). The highest proportion of HB9 + cells was induced in the presence of 0.1-1.0 ⁇ M of RA. RA at the dose over 1.0 ⁇ M resulted in degeneration of some cells in our chemically defined adherent cultures. In the absence of RA, or SHH, or both, there were very few HB9 + cells (Fig. 10D). All the HB9-expressing cells were stained with ? ⁇ -tubulin (Fig. 10C). Thus treatment with RA on early neuroectodermal cells is required for efficient induction of motor neurons.
- RA choline acetyltransferase
- the ChAT-expressing cells were largely localized to the cluster (Fig. 12A), corresponding to the localization of the HB9 + cells. These cells were mainly multipolar cells and had large somas of 15-20 ⁇ m in diameter, with some being as big as 30 ⁇ m (Fig. 12A, B). Co-expression of HB9 in the nuclei and ChAT in the soma and processes was observed after three weeks of culture (Fig. 12C). Most of the neurons were also positively stained for vesicular acetylcholine transporter (VAChT, Fig. 12D), which is essential for storage and release of acetylcholine.
- VAChT vesicular acetylcholine transporter
- Mouse ES cells have been first directed to neuroectodermal cells which are then treated with morphogens such as FGF8 and SHH for differentiation into dopaminergic neurons (Barberi, T., et al., Nat Biotechnol. 21 :1200-1207. 2003; Lee, S.H., et al.. Nat. Biotechnol. 18:675-679, 2000) or RA and SHH for motor neuron differentiation (Wichterie, H., et al., supra. 2002). These observations seem to fit the notion that neurons are specified from epithelium in the neural tube.
- the Sox1 -expressing cells generated from hES cells in our culture system resemble those in the neural tube, as they form neural tube-like structures and express Sox1 after two weeks of differentiation from hES cells which are equivalent to a six-day-old human embryo (Zhang, S.C, J_, Hematother. Stem Cell Res. 12:625-634, 2003).
- the neural tube forms at the end of third week of human gestation (Wood, H.B. and Episkopou, V., Mech. Dev.
- Sox1 is expressed by the neuroectoderm during the formation of the neural tube in animals (Pevny, L.H., et aj., Development 125:1967- 1978, 1998; Wood, H.B. and Episkopou, V., supra, 1999).
- Cur finding suggests that the specification of a class of neurons, at least large projection neurons such as motor neurons, begins before stem cells become Sox1 -expressing neuroectodermal cells and may thus explain why brain-derived neuroepithelial cells fail to generate projection neurons of a different regional identity.
- the functional motor neurons from the renewable source of hES cells offer generic human motor neurons for screening pharmaceuticals designed for treating motor neuron-related disorders such as ALS. These cells also provide a useful source for experimental cell replacement for motor neurons, which may someday lead to applications in patients with motor neuron diseases or spinal cord injury.
- Human ES cells (lines H1 and H9, passages 19 to 42) were cultured and passaged weekly on a feeder layer of irradiated embryonic mouse fibroblasts as described (Thomson, J.A., et al., supra. 1998). The undifferentiated state of ES cells were confirmed by typical morphology and expression of Gct4 and SSEA4.
- hES cells were aggregated for four days and then cultured on an adhesive plastic surface for ten days in F12/DMEM supplemented with N2, heparin (2 ng/ml), and FGF2 (20 ng/ml) or RA (Zhang, S.C, et aj., supra, 2001 ).
- the morphogen-treated neuroectodermal cells were plated onto omithine/laminin-coated coverslips in a neuronal differentiation medium, which consisted of Neurobasal medium (Gibco), N2 supplement, and cAMP (Sigma, IgM) in the presence of RA (0.1 ⁇ M) and SHH (10- 500 ng/ml, R&D) for one week. After that, BDNF, GDNF, and insulin-like growth factor-1 (IGF1) (10 ng/ml, PeproTech Inc.) were added to the medium and the concentration of SHH was reduced to 50 ng/ml.
- a neuronal differentiation medium which consisted of Neurobasal medium (Gibco), N2 supplement, and cAMP (Sigma, IgM) in the presence of RA (0.1 ⁇ M) and SHH (10- 500 ng/ml, R&D) for one week. After that, BDNF, GDNF, and insulin-like growth factor-1 (IGF1) (10
- VAChT (Chemicon, 1:1000), lsll/2 (S. Pfaff), Gtx2 (F. Vaccarino), and Plig2 (M.
- RT-PCR amplifications were performed from hES cell-derived neuroectodermal cells at different stages and motor neuron differentiation cultures.
- the following primers were used: HoxC ⁇ , 5'-TTTATGGGGCTCAGCAAGAGG-3 ⁇ 5'- TCCACTTCATCCTTCGGTTCTG-3', 318 bp; HoxC ⁇ , 5'-
- TGAGGGCTGTGTCTGTTCGG-3 4 ⁇ 9 bp; SHH, ⁇ '-CCAATTACAACCCCGACATC- 3', 5'-CCGAGTTCTCTGCTTTCACC-3', 339 bp; Nkx6.1 , 5'- ACACGAGACCCACTTTTTCCG-3', ⁇ '-TGCTGGACTTGTGCTTCTTCAAC-3', 33 ⁇ bp.
- Electrophysiological properties of hES cell-derived motor neurons were investigated in cultures differentiated for five to six weeks using whole-cell patch- clamp recording techniques (Gao, B.X., et al., J. Neurophvsiol. 79:2277-2287, 1998).
- Tetrodotoxin I ⁇ M, Sigma
- bicuculline 20 ⁇ M, Sigma
- strychnine ⁇ ⁇ M, Sigma
- D-2-amino- ⁇ -phosphonovaleric acid AP- ⁇ , 40 ⁇ M, Sigma
- 6-cyano-7- nitroquinoxaline-2,3-dione CNPX, 20 ⁇ M, RBI, Natick, MA
- 1% biocytin was added to the recording solution.
- Current- and voltage- clamp recordings were performed using a MultiClamp 700A amplifier (Axon Instruments, Union City, CA).
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gynecology & Obstetrics (AREA)
- Psychology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49883103P | 2003-08-29 | 2003-08-29 | |
US49957003P | 2003-09-02 | 2003-09-02 | |
PCT/US2004/027841 WO2005021720A2 (en) | 2003-08-29 | 2004-08-27 | Method of in vitro differentiation of neural stem cells, motor neurons and dopamine neurons from primate embryonic stem cells |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1670901A2 true EP1670901A2 (en) | 2006-06-21 |
EP1670901A4 EP1670901A4 (en) | 2007-09-05 |
Family
ID=34278616
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04782339A Withdrawn EP1670901A4 (en) | 2003-08-29 | 2004-08-27 | Method of in vitro differentiation of neural stem cells, motor neurons and dopamine neurons from primate embryonic stem cells |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1670901A4 (en) |
JP (2) | JP2007503811A (en) |
KR (2) | KR20060115351A (en) |
AU (1) | AU2004269361B2 (en) |
CA (1) | CA2536588C (en) |
GB (1) | GB2421029B (en) |
IL (2) | IL173832A (en) |
WO (1) | WO2005021720A2 (en) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8153424B2 (en) | 2001-10-03 | 2012-04-10 | Wisconsin Alumni Research Foundation | Method of in vitro differentiation of neural stem cells, motor neurons and dopamine neurons from primate embryonic stem cells |
US7588937B2 (en) | 2001-10-03 | 2009-09-15 | Wisconsin Alumni Research Foundation | Method of in vitro differentiation of neural stem cells, motor neurons and dopamine neurons from primate embryonic stem cells |
US7632679B2 (en) | 2002-07-16 | 2009-12-15 | The Trustees Of Columbia University In The City Of New York | Systems and methods for screening for modulators of neural differentiation |
JP4792290B2 (en) * | 2005-12-27 | 2011-10-12 | 財団法人 東京都医学総合研究所 | Method for producing neural stem cells |
EP2422799A3 (en) | 2006-03-07 | 2013-03-06 | Geeta Shroff | Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation |
KR100838013B1 (en) * | 2006-06-07 | 2008-06-12 | 제일약품주식회사 | Efficient Generation of Neural Progenitors, Neurons and Dopaminergic Neurons from Human Embryonic Stem Cells |
WO2009132156A1 (en) | 2008-04-22 | 2009-10-29 | Regenerative Research Foundation | Retinal pigment epithelial stem cells |
KR101168053B1 (en) * | 2009-11-06 | 2012-07-24 | 연세대학교 산학협력단 | Efficient and Universal Method for Neural Differentiation of Pluripotent Stem Cells |
CN103052707A (en) | 2010-07-30 | 2013-04-17 | 剑桥实业有限公司 | Corticogenesis of human pluripotent cells |
DK2694644T3 (en) | 2011-03-30 | 2018-04-16 | Cellular Dynamics Int Inc | Priming of pluripotent stem cells for neural differentiation |
JP6015112B2 (en) * | 2012-05-11 | 2016-10-26 | 株式会社ニコン | Cell evaluation apparatus, cell evaluation method and program |
RS61529B9 (en) * | 2015-11-12 | 2024-04-30 | Hoffmann La Roche | Oligonucleotides for inducing paternal ube3a expression |
JP2019506861A (en) | 2016-02-01 | 2019-03-14 | シーダーズ−サイナイ メディカル センター | System and method for enterocyte growth in a microfluidic device |
JPWO2017209290A1 (en) * | 2016-06-03 | 2019-04-11 | 国立大学法人京都大学 | Production and use of pluripotent stem cell-derived motor neurons |
JP6376196B2 (en) * | 2016-09-29 | 2018-08-22 | 株式会社ニコン | Cell evaluation apparatus, cell evaluation method and program |
WO2018140647A1 (en) | 2017-01-25 | 2018-08-02 | Cedars-Sinai Medical Center | In vitro induction of mammary-like differentiation from human pluripotent stem cells |
US11767513B2 (en) | 2017-03-14 | 2023-09-26 | Cedars-Sinai Medical Center | Neuromuscular junction |
US11414648B2 (en) | 2017-03-24 | 2022-08-16 | Cedars-Sinai Medical Center | Methods and compositions for production of fallopian tube epithelium |
CN108048399B (en) * | 2017-11-13 | 2021-03-23 | 昆明医科大学 | Method for inducing tree shrew dopamine neuron primary cell autophagy by METH |
JP2019106895A (en) * | 2017-12-15 | 2019-07-04 | インダストリー‐ユニバーシティー コーぺレーション ファンデーション ハンヤン ユニバーシティ | Method of differentiating neural stem cells or neural precursor cells into dopamine neurons |
EP3775161A4 (en) * | 2018-04-06 | 2022-04-06 | Cedars-Sinai Medical Center | Human pluripotent stem cell derived neurodegenerative disease models on a microfluidic chip |
WO2019195800A1 (en) | 2018-04-06 | 2019-10-10 | Cedars-Sinai Medical Center | Novel differentiation technique to generate dopaminergic neurons from induced pluripotent stem cells |
CN112839709A (en) * | 2018-06-06 | 2021-05-25 | 加利福尼亚大学董事会 | Neural stem cell compositions and methods for treating neurodegenerative diseases |
JP6798533B2 (en) * | 2018-07-26 | 2020-12-09 | 株式会社ニコン | Cell evaluation device, incubator and program |
US20220323507A1 (en) * | 2019-09-06 | 2022-10-13 | Keio University | Method for Producing Cell Aggregate Including Glial Progenitor Cells |
JP7235027B2 (en) * | 2020-11-16 | 2023-03-08 | 株式会社ニコン | Cell evaluation instruments, incubators and programs |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001083715A2 (en) * | 2000-05-01 | 2001-11-08 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the Secretary, | Derivation of midbrain dopaminergic neurons from embryonic stem cells |
WO2001088104A2 (en) * | 2000-05-17 | 2001-11-22 | Geron Corporation | Neural progenitor cell populations |
US20030068819A1 (en) * | 2001-10-03 | 2003-04-10 | Su-Chun Zhang | Method of in vitro differentiation of transplantatable neural precursor cells from primate embryonic stem cells |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7144997B2 (en) * | 1997-07-24 | 2006-12-05 | Curis, Inc. | Vertebrate embryonic patterning-inducing proteins, compositions and uses related therto |
EP0996456A4 (en) * | 1997-08-04 | 2003-07-09 | Univ California | Methods for treating neurological deficits |
CN100422315C (en) * | 2000-11-30 | 2008-10-01 | 斯坦姆荣公司 | Isolated homozygous stem cells differentiated cells derived therefrom and materials and methods for making and using same |
US20030211605A1 (en) * | 2001-05-01 | 2003-11-13 | Lee Sang-Hun | Derivation of midbrain dopaminergic neurons from embryonic stem cells |
-
2004
- 2004-08-27 WO PCT/US2004/027841 patent/WO2005021720A2/en active Application Filing
- 2004-08-27 GB GB0605851A patent/GB2421029B/en active Active
- 2004-08-27 KR KR1020067004226A patent/KR20060115351A/en not_active Application Discontinuation
- 2004-08-27 CA CA2536588A patent/CA2536588C/en active Active
- 2004-08-27 AU AU2004269361A patent/AU2004269361B2/en active Active
- 2004-08-27 JP JP2006524872A patent/JP2007503811A/en not_active Withdrawn
- 2004-08-27 EP EP04782339A patent/EP1670901A4/en not_active Withdrawn
- 2004-08-27 KR KR1020087028900A patent/KR20080109943A/en not_active Application Discontinuation
-
2006
- 2006-02-20 IL IL173832A patent/IL173832A/en active IP Right Grant
-
2009
- 2009-04-28 IL IL198450A patent/IL198450A/en active IP Right Grant
-
2010
- 2010-01-28 JP JP2010017013A patent/JP5529561B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001083715A2 (en) * | 2000-05-01 | 2001-11-08 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the Secretary, | Derivation of midbrain dopaminergic neurons from embryonic stem cells |
WO2001088104A2 (en) * | 2000-05-17 | 2001-11-22 | Geron Corporation | Neural progenitor cell populations |
US20030068819A1 (en) * | 2001-10-03 | 2003-04-10 | Su-Chun Zhang | Method of in vitro differentiation of transplantatable neural precursor cells from primate embryonic stem cells |
Non-Patent Citations (6)
Title |
---|
BAIN G ET AL: "Embryonic stem cells express neuronal properties in vitro" DEVELOPMENTAL BIOLOGY, ACADEMIC PRESS, NEW YORK, NY, US, vol. 168, no. 2, 1995, pages 342-357, XP002317725 ISSN: 0012-1606 * |
LI X ET AL: "Differentiation of human embryonic stem cells into motoneurons." SOCIETY FOR NEUROSCIENCE ABSTRACT VIEWER AND ITINERARY PLANNER, [Online] 2003, page ABSTRACT NO. 347.7, XP009087528 33RD ANNUAL MEETING OF THE SOCIETY OF NEUROSCIENCE; NEW ORLEANS, LA, USA; NOVEMBER 08-12, 2003 Retrieved from the Internet: URL:http://sfn.scholarone.com> [retrieved on 3007-07-30] * |
LI XUE-JUN ET AL: "Specification of motoneurons from human embryonic stem cells" NATURE BIOTECHNOLOGY, vol. 23, no. 2, February 2005 (2005-02), pages 215-221, XP009087451 ISSN: 1087-0156 * |
MUJTABA T ET AL: "Lineage-restricted neural precursors can be isolated from both the mouse neural tube and cultured ES cells" DEVELOPMENTAL BIOLOGY, ACADEMIC PRESS, NEW YORK, NY, US, vol. 214, no. 1, 1 October 1999 (1999-10-01), pages 113-127, XP002216609 ISSN: 0012-1606 * |
See also references of WO2005021720A2 * |
YAN YIPING ET AL: "Directed differentiation of dopaminergic neuronal subtypes from human embryonic stem cells" STEM CELLS (MIAMISBURG), vol. 23, no. 6, June 2005 (2005-06), pages 781-790, XP009087442 ISSN: 1066-5099 * |
Also Published As
Publication number | Publication date |
---|---|
WO2005021720A3 (en) | 2005-05-19 |
AU2004269361B2 (en) | 2010-05-20 |
JP2007503811A (en) | 2007-03-01 |
WO2005021720A2 (en) | 2005-03-10 |
IL173832A (en) | 2011-02-28 |
GB0605851D0 (en) | 2006-05-03 |
AU2004269361A1 (en) | 2005-03-10 |
CA2536588A1 (en) | 2005-03-10 |
IL198450A (en) | 2011-01-31 |
IL173832A0 (en) | 2006-07-05 |
EP1670901A4 (en) | 2007-09-05 |
GB2421029A (en) | 2006-06-14 |
JP2010162024A (en) | 2010-07-29 |
CA2536588C (en) | 2018-04-24 |
KR20060115351A (en) | 2006-11-08 |
KR20080109943A (en) | 2008-12-17 |
JP5529561B2 (en) | 2014-06-25 |
GB2421029B (en) | 2008-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Li | Zhang, l | |
US9080151B2 (en) | Method of in vitro differentiation of neural stem cells, motor neurons and dopamine neurons from primate embryonic stem cells | |
US8597945B2 (en) | Method of in vitro differentiation of neural stem cells, motor neurons and dopamine neurons from primate embryonic stem cells | |
CA2536588C (en) | Method of in vitro differentiation of neural stem cells, motor neurons and dopamine neurons from primate embryonic stem cells | |
US6887706B2 (en) | Method of in vitro differentiation of transplantable neural precursor cells from primate embryonic stem cells | |
US10093897B2 (en) | Generation of neuronal cells from pluripotent stem cells | |
Wernig et al. | Tau EGFP embryonic stem cells: an efficient tool for neuronal lineage selection and transplantation | |
EP2360241A1 (en) | Stem cells | |
US20090035285A1 (en) | Compositions and Methods for Enrichment of Neural Stem Cells Using Ceramide Analogs | |
CN115968401A (en) | Method for differentiating stem cells into dopaminergic progenitor cells | |
FROM | c12) United States Patent | |
EP1179046B1 (en) | Lineage-restricted precursor cells isolated from mouse neural tube and mouse embryonic stem cells | |
JP2024513912A (en) | Dopaminergic precursor cells (PRECURSOR CELL) and how to use them | |
US20190322982A1 (en) | Stem Cells from the Mammalian Neural Plate | |
CN117441011A (en) | Dopaminergic precursor cells and methods of use | |
AU4826200A (en) | Lineage-restricted precursor cells isolated from mouse neural tube and mouse embryonic stem cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20060324 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20070807 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12N 5/02 20060101AFI20050526BHEP Ipc: G01N 33/48 20060101ALI20070801BHEP Ipc: C12N 5/08 20060101ALI20070801BHEP Ipc: C12N 5/06 20060101ALI20070801BHEP |
|
17Q | First examination report despatched |
Effective date: 20110527 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20140808 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: C12N0005020000 Ipc: C12N0005079300 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: C12N0005020000 Ipc: C12N0005079300 Effective date: 20150107 |